natgillin/translations-raw huggingface dataset:
Lilly Deutschland GmbH Tel. + 49(0) 6172 273 2222
Lilly Deutschland GmbH Tel: + 49 (0) 6172 273 2222
Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222
Lilly Deutschland GmbH Tel: + 49 (0) 6172 273 2222
Lilly Deutschland GmbH Tel: + 49-(0) 6172 273 2222
Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222
Lilly Farma – Produtos Farmacêuticos, Lda Elanco Animal Health
LILLY PORTUGAL – Produtos Farmacêuticos, Lda
Lilly France S.A., rue du colonel Lilly, 67640 Fegersheim, Frankrig
Lilly France S.A.S., rue du colonel Lilly, 67640 Fegersheim, France
Lilly France S.A.S.
Eli Lilly Polska Sp. z o.o.
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, Frankrig
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France,
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, Frankrig.
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, Frankrig.
Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France,
Lilly France SAS
Eli Lilly Polska Sp. z o.o.
Lilly Hungária Kft.
Eli Lilly Ges. m.b.H.
Lilly Hungária Kft.
Lilly S.A.
Lilly Portugal - Produtos Farmacêuticos, Lda
Eli Lilly Hrvatska d.o.o.
Lilly Portugal - Produtos Farmacêuticos, Lda
Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351 21 412 66 00
Lilly S.A.
Charles de Giorgio Ltd.
Lilly S.A., Avda de la Industria, 30, Alcobendas, Madrid, 28108, Spanien
Lilly S.A., Avda de la Industria, 30, Alcobendas, Madrid, 28108, Spain
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spanien.
Lilly S.A, Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spanien.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spanien
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spanien
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spanien.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spanien.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
Limbus er en del af øjet.
The limbus is part of the eye.
Limbus indeholder limbale celler, som normalt hjælper med til at bevare øjets sundhed og nogle af disse er stamceller, som kan generere nye celler.
The limbus contains limbal cells which normally help to maintain the health of your eye and some of these are stem cells which can make new cells.
Limerick Irland
Ireland
limhindebetændelse
mucosal inflammation
Limpie con una toallita húmeda desechable el polvo que haya caído al romper el comprimido y tírela.
Powder spilled from the broken tablet should be wiped up with a damp disposable towel which must be thrown out.
Limpie con una toallita húmeda desechable el polvo que pudiera caer al romper el comprimido y tírela..
Powder eventually spilled from the broken tablet should be wiped up with a damp disposable towel, which must be discarded.
limus plasmakoncentrationen
everolimus concentrations (see
Linaclotid
Linaclotide
Linaclotid kan kun sjældent detekteres i plasma og metaboliseres ikke af lever cytomkrom P450 enzymer, og nedsat leverfunktion forventes derfor ikke at påvirke metabolismen eller clearance af modersubstansen eller dens metabolit.
Linaclotide is rarely detectable in plasma and is not metabolised by liver cytochrome P450 enzymes, therefore, hepatic impairment would not be expected to affect the metabolism or clearance of the parent drug or its metabolite.
Linaclotid kan sjældent detekteres i plasma efter administration af de anbefalede kliniske doser, og in vitro studier har vist, at linaclotid hverken er et substrat eller en hæmmer/induktor af cytochrom P450 enzymsystemet og ikke interagerer med en række almindelige efflux- og optagelsestransportører (se pkt.
Linaclotide is rarely detectable in plasma following administration of the recommended clinical doses and in vitro studies have shown that linaclotide is neither a substrate nor an inhibitor/inducer of the cytochrome P450 enzyme system and does not interact with a series of common efflux and uptake transporters (see section 5.2).
Linaclotid metaboliseres lokalt i mave-tarmkanalen til dets primære metabolit, des-tyrosin.
Linaclotide is metabolised locally within the gastrointestinal tract to its active primary metabolite, des- tyrosine.
Linaclotids sikkerhed og virkning hos børn og teenagere fra 0 til 18 år er endnu ikke klarlagt.
The safety and efficacy of linaclotide in children aged 0 to18 years have not yet been established.
Linagliptin + metformin + sulfonylurinstof
Linagliptin + Metformin + Sulphonylurea
Linagliptin 2,5 mg to gange dagligt1 + metformin HCl
Linagliptin 2.5 mg Twice Daily1 +
Linagliptin bør ikke anvendes under graviditeten.
As a precautionary measure, it is preferable to avoid the use of linagliptin during pregnancy.
Linagliptin hæmmer enzymet DPP-4 (dipeptidyl peptidase 4), et enzym, der er involveret i inaktiveringen af inkretinhormonerne GLP-1 og GIP (glucagonlignende peptid 1, glucoseafhængigt insulinotropt polypeptid).
Linagliptin is an inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase 4) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose- dependent insulinotropic polypeptide).
Linagliptin hæmmer enzymet DPP-4 (dipeptidyl-peptidase 4, EC 3.4.14.5), et enzym, der er involveret i inaktiveringen af inkretinhormonerne GLP-1 og GIP (glucagon-lignende peptid-1, glucoseafhængigt insulintropt polypeptid).
Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase 4, EC 3.4.14.5) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide1, glucose-dependent insulinotropic polypeptide).
Linagliptin i kombination med metformin og insulin
Linagliptin in combination with metformin and insulin
Linagliptin i tillæg til metformin og et sulfonylurinstof
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy
Linagliptin inducerer ikke CYP- isozymer.
It is not an inducer of CYP isozymes.
Linagliptin må ikke anvendes til patienter med type 1-diabetes eller til behandling af diabetisk ketoacidose.
Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Linagliptin som monoterapi
Linagliptin monotherapy
Linagliptin som monoterapi til patienter, hvor metforminbehandling er uegnet
Linagliptin as monotherapy in patients ineligible for metformin
Linagliptin som tillæg til metformin og et sulfonylurinstof
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy
Linagliptin som tillægsbehandling til patienter med svært nedsat nyrefunktion, 12 ugers placebokontrollerede data (med uændret baggrundsbehandling) og 40 ugers placebokontrolleret forlængelse (justerbar baggrundsbehandling).
Linagliptin as add-on therapy in patients with severe renal impairment, 12 week placebo-controlled data (stable background) and 40 week placebo-controlled extension (adjustable background)
Linagliptin som tillægsbehandling til ældre (> 70 år) med type 2-diabetes
Linagliptin as add-on therapy in elderly (age ≥ 70 years) with type 2 diabetes
Linagliptin som tillægsbehandling til ældre patienter (alder ≥ 70 år) med type 2-diabetes
Linagliptin as add-on therapy in elderly (age ≥ 70 years) with type 2 diabetes
Linagliptin tilhører en klasse af lægemidler, der kaldes DPP-4-hæmmere (dipeptidylpeptidase-4-hæmmere).
Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).
Linagliptin viste sig desuden at medføre signifikant reduktion i faste-plasma- glucose (FPG) og 2-timers postprandial glucose (PPG).
Linagliptin also showed significant improvements in fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG) compared to placebo.
Linagliptin viste sig desuden at medføre signifikant reduktion i faste-plasma-glucose (FPG) og 2- timers postprandial glucose (PPG).
Linagliptin also showed significant improvements in fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG) compared to placebo.
Linagliptin viste sig desuden at medføre signifikant reduktion i faste-plasma-glucose (FPG) og 2-timers postprandial glucose (PPG).
Linagliptin also showed significant improvements in patients fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG), compared to placebo.
Linagliptin+ insulin
Linagliptin + Insulin
Linagliptins sikkerhed og virkning hos børn og unge er endnu ikke klarlagt.
The safety and efficacy of linagliptin in children and adolescents has not yet been established.
Linde Healthcare AB SE-181 81 Lidingö Sverige
Linde Healthcare AB SE-181 81 Lidingö Sweden
Lindrer halsbrand.
Relieves heartburn
Lindring af betændelse og smerter ved såvel akutte som kroniske lidelser i bevægeapparatet hos heste der vejer mellem 500 og 600 kg.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.
Lindring af betændelse og smerter ved såvel akutte som kroniske lidelser i bevægeapparatet.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Lindring af inflammation og smerte ved såvel akutte som kroniske muskulo-skeletale lidelser hos hunde.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Lindring af inflammation og smerte ved såvel akutte som kroniske muskulo-skeletale lidelser hos hunde.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Lindring af inflammation og smerte ved såvel akutte som muskulo-skeletale lidelser.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Lindring af smerte i forbindelse med kolik hos hest.
Pain associated with equine colic.
Linearitet
NAME OF THE MEDICINAL PRODUCT
Linearitet / non-linearitet
Linearity/non-linearity
Linearitet/non-linearitet
Linearity
Linearitet/non-linearitet
Linearity/ non linearity
Linearitet/non-linearitet
Linearity/non linearity
Linearitet/non-linearitet:
Linearity
Linearitet/non-linearitet: Adefovirs farmakokinetik er proportional med doser, der gives som adefovirdipivoxil over dosisområdet 10-60 mg.
Linearity/non-linearity: The pharmacokinetics of adefovir are proportional to dose when given as adefovir dipivoxil over the dose range of 10 to 60 mg.
Linearitet/non-linearitet: Rasagilins farmakokinetik er lineær i doser over 0,5 – 2 mg.
Linearity/non-linearity: Rasagiline pharmacokinetics are linear with dose over the range of 0.5-2 mg.
Linearitet:  0,5 ‰ for udåndingsluftprøver, som varierer mellem 1 % og 7 % CO2-koncentration
Linearity:  0.5 ‰ for breath samples varying between 1 % and 7 % CO2-concentration
Linearitet: -0,5 ‰ for udåndingsluftprøver, som varierer mellem 1 % og 7 % CO2-koncentration
Linearity:  0.5 ‰ for breath samples varying between 1 % and 7 % CO2-concentration
Linezolid (mod infektioner, der skyldes bakterier).
linezolid (a medicine to treat bacterial infections) .
Linezolid (mod infektioner, der skyldes bakterier).
linezolid (a medicine to treat bacterial infections).
Lineær blandet farmakokinetisk/farmakodynamisk analyse indikerede ingen større stigning i gennemsnitligt QTcF-interval (dvs. større end 20 ms) ved Cmax for daratumumab.
Linear mixed PK-PD analyses indicated no large increase in mean QTcF interval (i.e., greater than 20ms) at daratumumab Cmax.
Lineær og dosisproportional stigning blev observeret for peak -plasmakoncentrationer og AUC.
Linear and dose proportional increases were observed for peak plasma concentration and area under the curve.
Liniaritet/non-liniaritet
Linearity/non linearity
Linjerne på skeen angiver mængden (i gram natriumphenylbutyrat).
Lines on the spoon indicate the amount (in gram of sodium phenylbutyrate).
Linjerne på skeen angiver mængden (i milligram para-aminosalicylsyre).
Lines on the spoon indicate the amount (in milligrams of para-aminosalicylic acid).
Link til indlægssedlen på EMA’s hjemmeside.
Placeholder including the weblink of the Package Leaflet on the EMA website
Linseopacitet: Efter behandling med bexaroten udviste nogle patienter en tidligere ubemærket linseopacitet eller en forandring i allerede tilstedeværende linseopacitet, uafhængigt af behandlingens varighed eller doseringsniveau.
Lens opacities: following bexarotene treatment, some patients were observed to have previously undetected lens opacities or a change in pre-existing lens opacities unrelated to treatment duration or dose level of exposure.
Lion Court, Farnham Road Bordon, Hampshire GU35 0NF Storbritannien
Lion Court, Farnham Road Bordon, Hampshire, GU35 0NF United Kingdom
Lion Court, Farnham Road Bordon, Hampshire, GU35 0NF Storbritannien
Lion Court, Farnham Road Bordon, Hampshire, GU35 0NF United Kingdom
lipase-hæmmere – anvendes til at behandle fedme pancreaslipase til substitutionsterapi.
lipase inhibitors – used to treat obesity lipase in pancreatic replacement therapies
lipaseaktivitet: 40.000 enheder*
lipolytic activity: 40,000 units
lipaseaktivitet: : 5.000 enheder*
lipolytic activity: 5,000 units
Lipegfilgrastim er et kovalent konjugat af filgrastim med et enkelt methoxypolyethylenglycol (PEG)- molekyle via en kulhydratlinker bestående af glycin, N-acetylneuraminsyre og N-acetylgalactosamin.
Lipegfilgrastim is a covalent conjugate of filgrastim with a single methoxy polyethylene glycol (PEG) molecule via a carbohydrate linker consisting of glycine, N-acetylneuraminic acid and
Lipegfilgrastim ligner filgrastim, der har været markedsført i hele EU i en række år.
Lipegfilgrastim is similar to filgrastim, which has been available in the European Union (EU) for a number of years.
Lipegfilgrastim virker på samme måde som naturligt dannet G‑CSF og øger produktionen af neutrofiler, så varigheden af neutropeni mindskes, og febril neutropeni (et infektionstegn) undgås hos patienter i kemoterapi.
Lipegfilgrastim acts in the same way as naturally produced G‑CSF, increasing the production of neutrophils and thereby helping to reduce the duration of neutropenia and to prevent febrile neutropenia (a sign of infection) in patients undergoing chemotherapy.
Lipide dysfunktioner bør behandles i henhold til klinisk praksis.
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Lipider, ændring i forhold til baseline
Lipids, Change from baseline
Lipider: kliniske undersøgelser har fastslået, at hyperlipidæmi er en virkning forbundet med bexaroten.
Lipids: hyperlipidaemia has been identified as an effect associated with the use of bexarotene in clinical studies.
Lipidprofilen skal bestemmes før behandlingsstart med Tasigna, vurderes ved måned 3 og 6 efter behandlingsstart og mindst 1 gang årligt ved kronisk behandling.
Lipid profiles should be determined prior to initiating Tasigna therapy, assessed at month 3 and 6 after initiating therapy and at least yearly during chronic therapy.
LIPIDSÆNKENDE LÆGEMIDLER
LIPID LOWERING MEDICINAL PRODUCTS
LIPIDSÆNKENDE MIDLER
ANTI-GOUT
LIPIDSÆNKENDE MIDLER
ANTIHYPERLIPIDAEMICS
LIPIDSÆNKENDE MIDLER
LIPID LOWERING AGENTS
LIPIDSÆNKENDE STOFFER
LIPID LOWERING MEDICINAL PRODUCTS
Lipidsænkende midler
Lipid lowering agents
Lipidsænkende midler
Lipid-lowering agents
Lipidsænkende midler
may cause myopathy, including
Lipidsænkende midler
Oral Contraceptives
Lipidsænkende præparater
Lipid lowering medicinal products
lipidsænkning
lipid-lowering
Lipoatrofi
Lipoatrophy
Lipodystrofi
Lipodystrophy
Lipodystrofi (fortykkelse eller fordybninger i huden) er ikke almindelig ( 1/1.000 til < 1/100).
Lipodystrophy (thickening or pitting of the skin) is uncommon ( 1/1,000 to <1/100).
Lipodystrofi (fortykkelse eller fordybninger i huden) er ikke almindelig ( 1/1.000 til <1/100).
Lipodystrophy (thickening or pitting of the skin) is uncommon ( 1/1,000 to <1/100).
Lipodystrofi (inklusiv lipohypertrofi og lipoatrofi) kan forekomme på injektionsstedet.
Lipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site.
Lipodystrofi kan forekomme på injektionsstedet som en konsekvens af ikke at skifte injektionssted inden for samme område.
Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Lipodystrofi ved indstiksstedet er ikke almindeligt forekommende ( 1/1.000 til < 1/100).
Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).
Lipodystrofi ved indstiksstedet er ikke almindeligt forekommende (1/1.000 til < 1/100).
Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).
Lipodystrofi ved indstiksstedet er ikke almindeligt forekommende.
Lipodystrophy at the injection site is uncommon.
Lipodystrofi:
Lipodystrophy:
Lipohyper- trofi
Lipohypertro- phy
Lipohypertrofi
Lipohyper- trophy
Lipohypertrofi
Lipohypertro- phy
Lipohypertrofi Cutis Laxa
Lipohypertrophy Cutis Laxa
lipohypertrofib,
phy)a,
Lipom (fedtknuder) (varer i gennemsnit 53 dage)
Lipoma (mean duration 53 days).
Lipom (gennemsnitlig varighed 53 dage)
Lipoma (mean duration 53 days).
Lipoproteinlipase er et vigtigt “første-trins” enzym i metaboliseringen af lipoproteiner efter fedtindtagelse med kosten.
Lipoprotein lipase is a key ‘first step’ enzyme in the metabolism of lipoproteins following fat intake with diet.
Liposom-indkapslet doxorubicin svarende til 50 mg doxorubicinhydrochlorid
Liposome–encapsulated doxorubicin corresponding to 50 mg doxorubicin hydrochloride
Liposom-indkapslet doxorubicin-citratkompleks svarende til 50 mg doxorubicinhydrochlorid (HCl).
Liposome–encapsulated doxorubicin–citrate complex corresponding to 50 mg doxorubicin hydrochloride (HCl).
Liposomal-indkapslet doxo- rubicin sammenlignet med konventionelt doxorubicin blev ikke fundet mere aktivt hos doxorubicin- resistente cellelinier in vitro.
Liposomal-encapsulated compared with conventional doxorubicin was not found more active in doxorubicin resistant cell lines in vitro.
Liposomalt Amphotericin B
Liposomal Amphotericin B
Liprolog 100 enheder/ml injektionsvæske, opløsning i cylinderampul Insulin lispro
Liprolog 100 units/ml solution for injection in cartridge Insulin lispro
Liprolog 100 enheder/ml injektionsvæske, opløsning i cylinderampul Insulin lispro (rDNA)
Liprolog 100 units/ml solution for injection in cartridge Insulin lispro (rDNA origin)
Liprolog 100 enheder/ml injektionsvæske, opløsning i hætteglas Insulin lispro (rDNA)
Liprolog 100 units/ml solution for injection in vial Insulin lispro (rDNA origin)
Liprolog 100 enheder/ml injektionsvæske, opløsning Insulin lispro
Liprolog 100 units/ml solution for injection in vial Insulin lispro
Liprolog 100 enheder/ml KwikPen og Liprolog 200 enheder/ml KwikPen
Liprolog 100 units/ml KwikPen and Liprolog 200 units/ml KwikPen
Liprolog 100 enheder/ml, injektionsvæske, opløsning er en steril klar farveløs vandig opløsning og indeholder 100 enheder insulin lispro per milliliter (100 enheder/ml) injektionsvæske.
Liprolog 100 units/ml, solution for injection is a sterile, clear, colourless, aqueous solution and contains 100 units of insulin lispro in each millilitre (100 units/ml) solution for injection.
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i cylinderampul (3 ml) Insulin lispro
Liprolog 100 units/ml solution for injection in cartridge insulin lispro
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i cylinderampul fremstilles af:
Liprolog 100 units/ml, solution for injection in cartridge is made by:
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i cylinderampul indeholder:
What Liprolog 100 units/ml solution for injection in cartridge contains
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i cylinderampuller
Liprolog 100 units/ml, solution for injection in cartridge
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i hætteglas
Liprolog 100 units/ml, solution for injection in vial
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i hætteglas fremstilles af:
Liprolog 100 units/ml, solution for injection in vial is made by:
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i hætteglas indeholder:
What Liprolog 100 units/ml solution for injection in vial contains
Liprolog 100 enheder/ml, injektionsvæske, opløsning, i hætteglas Insulin lispro
Liprolog 100 units/ml solution for injection in vial insulin lispro
Liprolog 200 enheder/ml
Liprolog 200 units/ml
Liprolog 200 enheder/ml injektionsvæske, opløsningen i den fyldte pen (KwikPennen) må KUN indsprøjtes med denne fyldte pen.
The Liprolog 200 units/ml solution for injection in your pre-filled pen (the KwikPen) should ONLY be injected with this pre-filled pen.
Liprolog 200 enheder/ml KwikPen
Liprolog 200 units/ml KwikPen
Liprolog 200 enheder/ml KwikPen leveres i pakninger med 5 fyldte penne samt flerstykspakninger med 2 x 5 fyldte penne.
The Liprolog 200 units/ml KwikPen comes in a pack of 5 pre-filled pens or multipacks of 2 x 5 pre-filled pens.
Liprolog 200 enheder/ml KwikPen, injektionsvæske, opløsning er en steril klar farveløs vandig opløsning og indeholder 200 enheder insulin lispro i hver milliliter (200 enheder/ml) injektionsvæske.
Liprolog 200 units/ml KwikPen, solution for injection is a sterile, clear, colourless, aqueous solution and contains 200 units of insulin lispro in each millilitre (200 units/ml) solution for injection.
Liprolog 200 enheder/ml KwikPen, injektionsvæske, opløsning indeholder:
What Liprolog 200 units/ml KwikPen solution for injection contains
Liprolog 200 enheder/ml KwikPen, injektionsvæske, opløsning Insulin lispro
Liprolog 200 units/ml KwikPen, solution for injection Insulin lispro
Liprolog 200 enheder/ml, injektionsvæske, opløsning, i fyldt pen.
Liprolog 200 units/ml solution for injection in pre-filled pen
Liprolog Basal 100 enheder/ml injektionsvæske, suspension i cylinderampul Insulin lispro
Liprolog Basal 100 units/ml suspension for injection in cartridge insulin lispro
Liprolog Basal 100 enheder/ml injektionsvæske, suspension i cylinderampul Insulin lispro protaminsuspension (rDNA)
Liprolog Basal 100 units/ml suspension for injection in cartridge Insulin lispro protamine suspension (rDNA origin)
Liprolog Basal 100 enheder/ml injektionsvæske, suspension i cylinderampul.
Liprolog Basal 100 units/ml suspension for injection in cartridge
Liprolog Basal 100 enheder/ml injektionsvæske, suspension i cylinderampuller indeholder:
What Liprolog Basal 100 units/ml suspension for injection in cartridge contains
Liprolog Basal 100 enheder/ml KwikPen injektionsvæske, suspension
Liprolog Basal 100 units/ml KwikPen, suspension for injection
Liprolog Basal 100 enheder/ml KwikPen injektionsvæske, suspension indeholder:
What Liprolog Basal 100 units/ml KwikPen, suspension for injection contains
Liprolog Basal 100 enheder/ml KwikPen injektionsvæske, suspension Insulin lispro
Liprolog Basal 100 units/ml KwikPen, suspension for injection insulin lispro
Liprolog Basal 100 enheder/ml KwikPen, injektionsvæske, suspension er en steril hvid suspension og indeholder 100 enheder insulin lispro per milliliter (100 enheder/ml) injektionsvæske.
Liprolog Basal 100 units/ml KwikPen, suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Liprolog Basal 100 enheder/ml KwikPen, injektionsvæske, suspension Insulin lispro protaminsuspension
Liprolog Basal 100 units/ml KwikPen, suspension for injection Insulin lispro protamine suspension
Liprolog Basal 100 enheder/ml, injektionsvæske, suspension er en steril hvid suspension og indeholder 100 enheder insulin lispro per milliliter (100 enheder/ml) injektionsvæske.
Liprolog Basal 100 units/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Liprolog Basal 100 enheder/ml, injektionsvæske, suspension, i cylinderampuller fremstilles af:
Liprolog Basal 100 units/ml KwikPen, suspension for injection is made by: